Windlas Biotech IPO Share Price : Exxaro Tiles Share Price
Windlas Biotech Ltd is amongst the top five players in the domestic pharmaceutical formulations Contract Development and Manufacturing Organization (“CDMO”) industry in India in terms of revenue.
With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low-solubility, company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.
The Company’s EBITDA increased by 47.04% from Rs. 29.52 Crores in the nine months ended December 31, 2019 to Rs. 43.4 Crores in the nine months ended December 31, 2020.
|Offer End||:||6 Aug 2021|
|Allotment Finalisation||:||11 Aug 2021|
|Refund Initiation||:||12 Aug 2021|
|Listing||:||16 Aug 2021|
RISKS IN RELATION TO THE FIRST OFFER
This being the first public issue of our Company, there has been no formal market for the Equity Shares of our Company. The face value of the Equity Shares is ₹5. The Floor Price, Cap Price and Offer Price should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding active and/or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.